{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:48:38Z","timestamp":1791726518904,"version":"4.3.4"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["T.0089.16"],"award-info":[{"award-number":["T.0089.16"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003134","name":"Fund for Research and Training in Industry and Agriculture","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003134","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005026","name":"Fondation contre le Cancer","doi-asserted-by":"publisher","award":["F\/2016\/837"],"award-info":[{"award-number":["F\/2016\/837"]}],"id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016132","name":"Walloon Region","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"European Research Council","doi-asserted-by":"publisher","award":["TARG-SUP 682818"],"award-info":[{"award-number":["TARG-SUP 682818"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018985","name":"Waalse Gewest","doi-asserted-by":"publisher","award":["1610119"],"award-info":[{"award-number":["1610119"]}],"id":[{"id":"10.13039\/100018985","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.bcp.2021.114697","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T01:50:44Z","timestamp":1626918644000},"page":"114697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":115,"special_numbering":"C","title":["Targeting immunosuppression by TGF-\u03b21 for cancer immunotherapy"],"prefix":"10.1016","volume":"192","author":[{"given":"Gr\u00e9goire","family":"de Streel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2021.114697_b0005","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41580-018-0007-0","article-title":"Contextual determinants of TGFbeta action in development, immunity and cancer","volume":"19","author":"David","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2021.114697_b0010","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1073\/pnas.90.2.770","article-title":"Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death","volume":"90","author":"Kulkarni","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2021.114697_b0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032713-120257","article-title":"TGF-beta activation and function in immunity","volume":"32","author":"Travis","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bcp.2021.114697_b0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076186","article-title":"GARP is regulated by miRNAs and controls latent TGF-\u03b21 production by human regulatory T cells","volume":"8","author":"Gauthy","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcp.2021.114697_b0025","article-title":"Identification of a regulatory T cell specific cell surface molecule that mediates suppressive signals and induces Foxp3 expression","volume":"3","author":"Wang","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcp.2021.114697_b0030","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1002\/eji.200939684","article-title":"Membrane protein GARP is a receptor for latent TGF-\u03b2 on the surface of activated human Treg","volume":"39","author":"Stockis","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.bcp.2021.114697_b0035","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1111\/j.1582-4934.2009.00782.x","article-title":"GARP: a key receptor controlling FOXP3 in human regulatory T cells","volume":"13","author":"Probst-Kepper","year":"2009","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.bcp.2021.114697_b0040","doi-asserted-by":"crossref","first-page":"391","DOI":"10.4049\/jimmunol.1601882","article-title":"Cutting edge: active TGF-beta1 Released from GARP\/TGF-beta1 complexes on the surface of stimulated human B lymphocytes increases class-switch recombination and production of IgA","volume":"199","author":"Dedobbeleer","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2021.114697_b0045","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jhep.2014.04.027","article-title":"TGF-\u03b2-dependent induction of CD4(+)CD25(+)Foxp3(+) Tregs by liver sinusoidal endothelial cells","volume":"61","author":"Carambia","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bcp.2021.114697_b0050","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1182\/blood-2006-07-036269","article-title":"Comparative gene expression profiling of in vitro differentiated megakaryocytes and erythroblasts identifies novel activatory and inhibitory platelet membrane proteins","volume":"109","author":"Macaulay","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2021.114697_b0055","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/stem.1821","article-title":"Mesenchymal stromal cells express GARP\/LRRC32 on their surface: effects on their biology and immunomodulatory capacity","volume":"33","author":"Carrillo-Galvez","year":"2015","journal-title":"Stem Cells"},{"key":"10.1016\/j.bcp.2021.114697_b0060","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.4049\/jimmunol.1500139","article-title":"Hepatic stellate cells inhibit T cells through active TGF-\u03b21 from a cell surface-bound latent TGF-\u03b21\/GARP complex","volume":"195","author":"Li","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2021.114697_b0065","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cell.2018.05.027","article-title":"A Milieu molecule for TGF-beta required for microglia function in the nervous system","volume":"174","author":"Qin","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2021.114697_b0070","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1083\/jcb.200611044","article-title":"Absence of integrin-mediated TGFbeta1 activation in vivo recapitulates the phenotype of TGFbeta1-null mice","volume":"176","author":"Yang","year":"2007","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bcp.2021.114697_b0075","doi-asserted-by":"crossref","first-page":"288ra279","DOI":"10.1126\/scitranslmed.aaa5094","article-title":"The \u03b1V\u03b21 integrin plays a critical in vivo role in tissue fibrosis","volume":"7","author":"Reed","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcp.2021.114697_b0080","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1083\/jcb.200312172","article-title":"Integrin \u03b1V\u03b26-mediated activation of latent TGF-\u03b2 requires the latent TGF-\u03b2 binding protein-1","volume":"165","author":"Annes","year":"2004","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bcp.2021.114697_b0085","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature10152","article-title":"Latent TGF-beta structure and activation","volume":"474","author":"Shi","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2021.114697_b0090","doi-asserted-by":"crossref","first-page":"E10161","DOI":"10.1073\/pnas.1710680114","article-title":"Blocking immunosuppression by human Tregs in vivo with antibodies targeting integrin alphaVbeta8","volume":"114","author":"Stockis","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2021.114697_b0095","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.4049\/jimmunol.1401102","article-title":"Release of active TGF-\u03b21 from the latent TGF-\u03b21\/GARP complex on T regulatory cells is mediated by integrin \u03b28","volume":"193","author":"Edwards","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2021.114697_b0100","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122591","article-title":"Integrin alphavbeta8-expressing tumor cells evade host immunity by regulating TGF-beta activation in immune cells","volume":"3","author":"Takasaka","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.bcp.2021.114697_b0105","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.immuni.2015.04.012","article-title":"Integrin \u03b1V\u03b28-mediated TGF-\u03b2 activation by effector regulatory T cells is essential for suppression of T-cell-mediated inflammation","volume":"42","author":"Worthington","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2021.114697_b0110","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1083\/jcb.200109100","article-title":"The integrin \u03b1V\u03b28 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-\u03b21","volume":"157","author":"Mu","year":"2002","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bcp.2021.114697_b0115","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1084\/jem.20171491","article-title":"Human monocytes and macrophages regulate immune tolerance via integrin alphavbeta8-mediated TGFbeta activation","volume":"215","author":"Kelly","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcp.2021.114697_b0120","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1126\/science.aau2909","article-title":"Structural basis of latent TGF-beta1 presentation and activation by GARP on human regulatory T cells","volume":"362","author":"Li\u00e9nart","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.bcp.2021.114697_b0125","doi-asserted-by":"crossref","first-page":"284ra256","DOI":"10.1126\/scitranslmed.aaa1983","article-title":"Monoclonal antibodies against GARP\/TGF-beta1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo","volume":"7","author":"Cuende","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcp.2021.114697_b0130","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.cell.2019.12.030","article-title":"Cryo-EM reveals integrin-mediated TGF-beta activation without release from latent TGF-beta","volume":"180","author":"Campbell","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2021.114697_b0135","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2008.07.001","article-title":"TGFbeta in cancer","volume":"134","author":"Massague","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2021.114697_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ceb.2017.10.001","article-title":"Mechanistic insight into contextual TGF-beta signaling","volume":"51","author":"Zhang","year":"2018","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.bcp.2021.114697_b0145","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022129","article-title":"Non-Smad Signaling Pathways of the TGF-beta Family","volume":"9","author":"Zhang","year":"2017","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.bcp.2021.114697_b0150","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022053","article-title":"Signaling Receptors for TGF-beta Family Members","volume":"8","author":"Heldin","year":"2016","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.bcp.2021.114697_b0155","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aav5183","article-title":"Specificity, versatility, and control of TGF-beta family signaling","volume":"12","author":"Derynck","year":"2019","journal-title":"Sci. Signal"},{"key":"10.1016\/j.bcp.2021.114697_b0160","doi-asserted-by":"crossref","DOI":"10.3390\/biom10030487","article-title":"TGF-beta signaling","volume":"10","author":"Tzavlaki","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.bcp.2021.114697_b0165","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ceb.2009.01.021","article-title":"Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition","volume":"21","author":"Heldin","year":"2009","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.bcp.2021.114697_b0170","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41571-020-0403-1","article-title":"TGFbeta biology in cancer progression and immunotherapy","volume":"18","author":"Derynck","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcp.2021.114697_b0175","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2853","article-title":"TGFbeta signalling: a complex web in cancer progression","volume":"10","author":"Ikushima","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2021.114697_b0180","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ccr.2007.08.020","article-title":"Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia","volume":"12","author":"Guasch","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2021.114697_b0185","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9050042","article-title":"KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 mutations in pancreatic cancer","volume":"9","author":"Cicenas","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bcp.2021.114697_b0190","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1042\/bj20031886","article-title":"Molecular and functional consequences of Smad4 C-terminal missense mutations in colorectal tumour cells","volume":"379","author":"De Bosscher","year":"2004","journal-title":"Biochem. J."},{"key":"10.1016\/j.bcp.2021.114697_b0195","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1158\/1078-0432.CCR-09-0227","article-title":"SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer","volume":"15","author":"Blackford","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2021.114697_b0200","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/ng.3225","article-title":"Stromal gene expression defines poor-prognosis subtypes in colorectal cancer","volume":"47","author":"Calon","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcp.2021.114697_b0205","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.semcancer.2013.12.008","article-title":"TGF-beta in CAF-mediated tumor growth and metastasis","volume":"25","author":"Calon","year":"2014","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bcp.2021.114697_b0210","doi-asserted-by":"crossref","first-page":"7160","DOI":"10.1073\/pnas.1014506108","article-title":"Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer","volume":"108","author":"Navab","year":"2011","journal-title":"PNAS"},{"key":"10.1016\/j.bcp.2021.114697_b0215","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022210","article-title":"TGF-beta Signaling in Control of Cardiovascular Function","volume":"10","author":"Goumans","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.bcp.2021.114697_b0220","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41571-020-0403-1","article-title":"TGFbeta biology in cancer progression and immunotherapy","volume":"18","author":"Derynck","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcp.2021.114697_b0225","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.immuni.2010.04.012","article-title":"Transforming growth factor-beta signaling curbs thymic negative selection promoting regulatory T cell development","volume":"32","author":"Ouyang","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2021.114697_b0230","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.immuni.2006.07.012","article-title":"Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-beta receptor","volume":"25","author":"Marie","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2021.114697_b0235","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1074-7613(00)80170-3","article-title":"Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease","volume":"12","author":"Gorelik","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2021.114697_b0240","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/nm1001-1118","article-title":"Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells","volume":"7","author":"Gorelik","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2021.114697_b0245","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccr.2005.10.012","article-title":"TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance","volume":"8","author":"Thomas","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2021.114697_b0250","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.immuni.2011.04.019","article-title":"T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-beta1 cytokine","volume":"35","author":"Donkor","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2021.114697_b0255","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/2159-8290.CD-15-1347","article-title":"TGFbeta1-mediated SMAD3 enhances PD-1 expression on antigen-specific T cells in cancer","volume":"6","author":"Park","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bcp.2021.114697_b0260","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nri704","article-title":"Transforming growth factor-beta in T-cell biology","volume":"2","author":"Gorelik","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bcp.2021.114697_b0265","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.cell.2008.07.025","article-title":"TGF-beta: a master of all T cell trades","volume":"134","author":"Li","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2021.114697_b0270","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10060194","article-title":"TGF-beta in T cell biology: implications for cancer immunotherapy","volume":"10","author":"Dahmani","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.bcp.2021.114697_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.03.048","article-title":"T Cell Factor 1 Suppresses CD103+ Lung Tissue-Resident Memory T Cell Development","volume":"31","author":"Wu","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.bcp.2021.114697_b0280","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41590-020-0674-9","article-title":"Type 1 Treg cells promote the generation of CD8(+) tissue-resident memory T cells","volume":"21","author":"Ferreira","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bcp.2021.114697_b0285","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth factor-beta signaling in immunity and cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2021.114697_b0290","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/bs.ai.2017.01.001","article-title":"Regulation of Innate and Adaptive Immunity by TGFbeta","volume":"134","author":"Kelly","year":"2017","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.bcp.2021.114697_b0295","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.immuni.2011.03.005","article-title":"Autocrine transforming growth factor-beta1 promotes in vivo Th17 cell differentiation","volume":"34","author":"Gutcher","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2021.114697_b0300","first-page":"4766","article-title":"Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer","volume":"61","author":"Woo","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2021.114697_b0305","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.4049\/jimmunol.169.5.2756","article-title":"Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma","volume":"169","author":"Liyanage","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2021.114697_b0310","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.4049\/jimmunol.173.2.1444","article-title":"Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells","volume":"173","author":"Viguier","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2021.114697_b0315","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2021.114697_b0320","doi-asserted-by":"crossref","first-page":"15179","DOI":"10.1038\/srep15179","article-title":"Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis","volume":"5","author":"Shang","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2021.114697_b0325","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/eji.200838807","article-title":"Comparison of stable human Treg and Th clones by transcriptional profiling","volume":"39","author":"Stockis","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.bcp.2021.114697_b0330","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1073\/pnas.0408197102","article-title":"Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo","volume":"102","author":"Chen","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2021.114697_b0335","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1038\/s41467-020-17811-3","article-title":"Selective inhibition of TGF-\u03b21 produced by GARP-expressing Tregs overcomes resistance to PD-1\/PD-L1 blockade in cancer","volume":"11","author":"de Streel","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2021.114697_b0340","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.4049\/jimmunol.158.5.2065","article-title":"TGF-beta suppresses IFN-gamma induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression","volume":"158","author":"Lee","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2021.114697_b0345","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nri2808","article-title":"The polarization of immune cells in the tumour environment by TGFbeta","volume":"10","author":"Flavell","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bcp.2021.114697_b0350","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1189\/jlb.1211639","article-title":"Deletion of TGF-beta signaling in myeloid cells enhances their anti-tumorigenic properties","volume":"92","author":"Novitskiy","year":"2012","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.bcp.2021.114697_b0355","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1186\/s12885-019-5917-5","article-title":"Prognostic value of TGF-beta in lung cancer: systematic review and meta-analysis","volume":"19","author":"Li","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcp.2021.114697_b0360","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/1097-0142(20010301)91:5<964::AID-CNCR1086>3.0.CO;2-O","article-title":"Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma","volume":"91","author":"Hasegawa","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2021.114697_b0365","doi-asserted-by":"crossref","first-page":"34387","DOI":"10.18632\/oncotarget.16166","article-title":"High TGF-beta1 expression predicts poor disease prognosis in hepatocellular carcinoma patients","volume":"8","author":"Peng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2021.114697_b0370","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/sj.bjc.6603877","article-title":"Tissue level, activation and cellular localisation of TGF-beta1 and association with survival in gastric cancer patients","volume":"97","author":"Hawinkels","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2021.114697_b0375","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1590\/S1807-59322011000700004","article-title":"Tgf-beta1 expression as a biomarker of poor prognosis in prostate cancer","volume":"66","author":"Reis","year":"2011","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.bcp.2021.114697_b0380","first-page":"4479","article-title":"Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway","volume":"9","author":"Herbertz","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bcp.2021.114697_b0385","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1177\/0192623311416259","article-title":"Induction of heart valve lesions by small-molecule ALK5 inhibitors","volume":"39","author":"Anderton","year":"2011","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.bcp.2021.114697_b0390","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1158\/1078-0432.CCR-14-1380","article-title":"First-in-human dose study of the novel transforming growth factor-beta receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma","volume":"21","author":"Rodon","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2021.114697_b0395","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/neuonc\/now009","article-title":"A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma","volume":"18","author":"Brandes","year":"2016","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bcp.2021.114697_b0400","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.trecan.2016.11.008","article-title":"Targeting TGF-beta Signaling in Cancer","volume":"3","author":"Colak","year":"2017","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bcp.2021.114697_b0405","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/s41416-018-0246-z","article-title":"Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer","volume":"119","author":"Melisi","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2021.114697_b0410","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090353","article-title":"Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma","volume":"9","author":"Morris","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcp.2021.114697_b0415","doi-asserted-by":"crossref","DOI":"10.4161\/onci.26218","article-title":"Immunological effects of the TGFbeta-blocking antibody GC1008 in malignant pleural mesothelioma patients","volume":"2","author":"Stevenson","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bcp.2021.114697_b0420","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00280-017-3245-5","article-title":"A phase 1 study of anti-TGFbeta receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors","volume":"79","author":"Tolcher","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114697_b0425","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1046\/j.1432-1327.1998.2540505.x","article-title":"Chimeric extracellular domain type II transforming growth factor (TGF)-beta receptor fused to the Fc region of human immunoglobulin as a TGF-beta antagonist","volume":"254","author":"Komesli","year":"1998","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.bcp.2021.114697_b0430","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1172\/JCI0215234","article-title":"Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases","volume":"109","author":"Muraoka","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2021.114697_b0435","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan5488","article-title":"Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-beta","volume":"10","author":"Lan","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcp.2021.114697_b0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2020.03.003","article-title":"Bintrafusp Alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in second-line treatment of patients with NSCLC: results from an expansion cohort of a phase 1 trial","author":"Paz-Ares","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.bcp.2021.114697_b0445","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41467-017-02696-6","article-title":"Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFbeta enhance the efficacy of cancer immunotherapy","volume":"9","author":"Ravi","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2021.114697_b0450","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay8456","article-title":"Selective inhibition of TGFbeta1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape","volume":"12","author":"Martin","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcp.2021.114697_b0455","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.cell.2017.01.010","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"168","author":"Hugo","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2021.114697_b0460","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221003105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221003105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:54:37Z","timestamp":1777391677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295221003105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":92,"alternative-id":["S0006295221003105"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114697","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting immunosuppression by TGF-\u03b21 for cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114697","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"114697"}}